Alembic Pharmaceuticals Ltd
Craig Salmon has extensive experience in the pharmaceutical industry, having held various leadership positions. Craig started their career at Sandoz, where they served as the Director of National Accounts from July 2005 to October 2008. Following this, they were appointed as the Vice President of Sales at Sandoz from October 2008 to May 2009. Craig then joined Fera Pharmaceuticals as the Executive Vice President of Sales in June 2009, where they remained until May 2015. Currently, they are the President of US Operations at Alembic Pharmaceuticals Inc, a position they have held since May 2015.
Craig Salmon attended North Carolina State University, although no information is available regarding the specific years of their enrollment or the degree they pursued.
This person is not in any teams
This person is not in any offices
Alembic Pharmaceuticals Ltd
8 followers
Alembic Pharmaceuticals Limited is a pharmaceutical company. The Company is engaged developing formulations and active pharmaceutical ingredients (API). The Company focuses on anti-infective, analgesic and, cough and cold therapies. It also focuses on therapies, such as cardiology, diabetes, gynecology, gastrointestinal, orthopedic, dermatology and ophthalmology. Its APIs include independent manufacturing blocks for Macrolides, non-steroidal anti-inflammatory drugs (NSAIDs) and other drugs. The Company offers international and domestic formulations. Under domestic formulation, it offers Branded Formulations and Generic formulations. Its domestic formulation include Roxid, Zofix, Althrocin, Tellzy AH, Revas H, Lactonic, Folinal, Gestofit, Glisen 1/2, Glimser 1/2, Veldrop, Azithral, Brinzemic and Neolap. Its generic formulations include Cetral, Ephedrex CD, Sicor, Worid, Alcephin, Alcizon, Baciclox, Comeba, Furobid, O Win Suspension, O win T, Silomag Gel, Pentab, Aginal AT and Pyremol.